Selective inhibitors of picornavirus replication

Medicinal Research Reviews

Volumn 28, Issue 6, 2008, Pages 823-884

  De Palma, Armando M ^a   Vliegen, Inge ^a   De Clercq, Erik ^a   Neyts, Johan ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

Antiviral; Enterovirus; Picornavirus

Indexed keywords

1 [5 (4 BROMOPHENOXY)PENTYL] 3 (4 PYRIDYL) 2 IMIDAZOLIDINONE; 1 [6 (2 CHLORO 4 METHOXYPHENOXY) HEXYL]IMIDAZOLE HYDROCHLORIDE; 3 METHOXY 6 [4 (3 METHYLPHENYL) 1 PIPERAZINYL]PYRIDAZINE; 4' ETHOXY 2' HYDROXY 4,6' DIMETHOXYCHALCONE; 5 [5 [2,6 DICHLORO 4 (4,5 DIHYDRO 2 OXAZOLYL)PHENOXY]PENTYL] 3 METHYLISOXAZOLE; ANTIVIRUS AGENT; BIPHENYL DERIVATIVE; BPROZ 194; BTA 188; BTA 39; BTA 798; CHALCONE DERIVATIVE; DBPR 103; DISOXARIL; IMIDAZOLE DERIVATIVE; IMIDAZOLIDINE DERIVATIVE; ISOXAZOLE DERIVATIVE; PIRODAVIR; PLECONARIL; PROTEINASE INHIBITOR; R 618737; RUPINTRIVIR; SCH 38057; SCH 47802; SCH 48973; SCH 48974; SDZ 35 682; SDZ 880 061; UNCLASSIFIED DRUG; UNINDEXED DRUG; WIN 52452; WIN 56291; WIN 58768; WIN 61893;

CLINICAL TRIAL; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG INHIBITION; DRUG METABOLISM; DRUG STRUCTURE; FOOD AND DRUG ADMINISTRATION; HUMAN; MENINGITIS; MYOCARDITIS; NONHUMAN; PICORNAVIRUS; PICORNAVIRUS INFECTION; REVIEW; VIRUS REPLICATION;

ANTIVIRAL AGENTS; DNA REPLICATION; MODELS, BIOLOGICAL; PICORNAVIRIDAE; PICORNAVIRIDAE INFECTIONS; PROTEASE INHIBITORS;

EID: 53649106470     PISSN: 01986325     EISSN: None     Source Type: Journal    
DOI: 10.1002/med.20125     Document Type: Review

References (376)

1. Grubman MJ, Baxt B. Foot-and-mouth disease. Clin Microbiol Rev 2004;17:465-493.
2. Thompson D, Muriel P, Russell D, Osborne P, Bromley A, Rowland M, Creigh-Tyte S, Brown C. Economic costs of the foot and mouth disease outbreak in the United Kingdom in 2001. Rev Sci Tech 2002;21:675-687.
3. Yang PC, Chu RM, Chung WB, Sung HT. Epidemiological characteristics and financial costs of the 1997 foot-and-mouth disease epidemic in Taiwan. Vet Rec 1999;145:731-734.
4. Mahy BW. Introduction and history of foot-and-mouth disease virus. Curr Top Microbiol Immunol 2005;288:1-8.
5. Brahic M, Bureau JF, Michiels T. The genetics of the persistent infection and demyelinating disease caused by Theiler's virus. Annu Rev Microbiol 2005;59:279-298.
6. Brewer LA, Lwamba HC, Murtaugh MP, Palmenberg AC, Brown C, Njenga MK. Porcine encephalomyocarditis virus persists in pig myocardium and infects human myocardial cells. J Virol 2001;75:11621-11629.
7. Gelmetti D, Meroni A, Brocchi E, Koenen F, Cammarata G. Pathogenesis of encephalomyocarditis experimental infection in young piglets: A potential animal model to study viral myocarditis. Vet Res 2006;37:15-23.
8. Racaniello VR. One hundred years of poliovirus pathogenesis. Virology 2006;344:9-16.
9. Sabin AB, Ramos-Alvarez M, Alvarez-Amezquita J, Pelon W, Michaels RH, Spigland I, Koch MA, Barnes JM, Rhim JS. Live, orally given poliovirus vaccine. Effects of rapid mass immunization on population under conditions of massive enteric infection with other viruses. JAMA 1960;173:1521-1526.
10. Thompson KM, Tebbens RJ. Eradication versus control for poliomyelitis: An economic analysis. Lancet 2007;369:1363-1371.
11. Sawyer MH. Enterovirus infections: Diagnosis and treatment. Semin Pediatr Infect Dis 2002;13:40-47.
12. Rotbart HA. Antiviral therapy for enteroviruses and rhinoviruses. Antivir Chem Chemother 2000;11:261-271.
13. Turner RB. The common cold. Pediatr Ann 1998;27:790-795.
14. Mallia P, Contoli M, Caramori G, Pandit A, Johnston SL, Papi A. Exacerbations of asthma and chronic obstructive pulmonary disease (COPD): Focus on virus induced exacerbations. Curr Pharm Des 2007;13:73-97.
15. Hershenson MB, Johnston SL. Rhinovirus infections: More than a common cold. Am J Respir Crit Care Med 2006;174:1284-1285.
16. Brundage SC, Fitzpatrick AN. Hepatitis A. Am Fam Physician 2006;73:2162-2168.
17. Stanway G, Joki-Korpela P, Hyypia T. Human parechoviruses-Biology and clinical significance. Rev Med Virol 2000;10:57-69.
18. Jimenez-Clavero MA, Fernandez C, Ortiz JA, Pro J, Carbonell G, Tarazona JV, Roblas N, Ley V. Teschoviruses as indicators of porcine fecal contamination of surface water. Appl Environ Microbiol 2003;69:6311-6315.
19. Kaku Y, Sarai A, Murakami Y. Genetic reclassification of porcine enteroviruses. J Gen Virol 2001;82:417-424.
20. Huang JA, Ficorilli N, Hartley CA, Wilcox RS, Weiss M, Studdert MJ. Equine rhinitis B virus: A new serotype. J Gen Virol 2001;82:2641-2645.
21. Black WD, Wilcox RS, Stevenson RA, Hartley CA, Ficorilli NP, Gilkerson JR, Studdert MJ. Prevalence of serum neutralising antibody to equine rhinitis Avirus (ERAV), equine rhinitis B virus 1 (ERBV1) and ER BV2. Vet Microbiol 2007;119:65-71.
22. Yamashita T, Kobayashi S, Sakae K, Nakata S, Chiba S, Ishihara Y, Isomura S. Isolation of cytopathic small round viruses with BS-C-1 cells from patients with gastroenteritis. J Infect Dis 1991;164:954-957.
23. Yamashita T, Sakae K, Tsuzuki H, Suzuki Y, Ishikawa N, Takeda N, Miyamura T, Yamazaki S. Complete nucleotide sequence and genetic organization of Aichi virus, a distinct member of the Picornaviridae associated with acute gastroenteritis in humans. J Virol 1998;72:8408-8412.
24. Michael G. Rossmann. Picornavirus structure overview. In Bert L. Semler, Eckard Wimmer, editors. Molecular biology of picornaviruses. 1 edition. Washington, DC: American Society for Microbiology; 2002. pp 27-38.
25. Rossmann MG, Arnold E, Erickson JW, Frankenberger EA, Griffith JP, Hecht HJ, Johnson JE, Kamer G, Luo M, Mosser AG. Structure of a human common cold virus and functional relationship to other picornaviruses. Nature 1985;317:145-153.
26. Bedard KM, Semler BL. Regulation of picornavirus gene expression. Microbes Infect 2004;6:702-713.
27. Carrasco L. Picornavirus inhibitors. Pharmacol Ther 1994;64:215-290.
28. Evans DJ, Almond JW. Cell receptors for picornaviruses as determinants of cell tropism and pathogenesis. Trends Microbiol 1998;6:198-202.
29. Rossmann MG, He Y, Kuhn RJ. Picornavirus-receptor interactions. Trends Microbiol 2002;10:324-331.
30. Rossmann MG. The canyon hypothesis. Viral Immunol 1989;2:143-161.
31. McKinlay MA, Pevear DC, Rossmann MG. Treatment of the picornavirus common cold by inhibitors of viral uncoating and attachment. Annu Rev Microbiol 1992;46:635-654.
32. Rossmann MG, Bella J, Kolatkar PR, He Y, Wimmer E, Kuhn RJ, Baker TS. Cell recognition and entry by rhino- and enteroviruses. Virology 2000;269:239-247.
33. Jackson T, Mould AP, Sheppard D, King AM. Integrin alphavbeta1 is a receptor for foot-and-mouth disease virus. J Virol 2002;76:935-941.
34. Neff S, Sa-Carvalho D, Rieder E, Mason PW, Blystone SD, Brown EJ, Baxt B. Foot-and-mouth disease virus virulent for cattle utilizes the integrin alpha(v)beta3 as its receptor. J Virol 1998;72:3587-3594.
35. Jackson T, Clark S, Berryman S, Burman A, Cambier S, Mu D, Nishimura S, King AM. Integrin alphavbeta8 functions as a receptor for foot-and-mouth disease virus: Role of the beta-chain cytodomain in integrin-mediated infection. J Virol 2004;78:4533-4540.
36. Williams CH, Kajander T, Hyypia T, Jackson T, Sheppard D, Stanway G. Integrin alpha v beta 6 is an RGD-dependent receptor for coxsackievirus A9. J Virol 2004;78:6967-6973.
37. Berinstein A, Roivainen M, Hovi T, Mason PW, Baxt B. Antibodies to the vitronectin receptor (integrin alpha V beta 3) inhibit binding and infection of foot-and-mouth disease virus to cultured cells. J Virol 1995;69:2664-2666.
38. Jackson T, Sheppard D, Denyer M, Blakemore W, King AM. The epithelial integrin alphavbeta6 is a receptor for foot-and-mouth disease virus. J Virol 2000;74:4949-4956.
39. Mason PW, Rieder E, Baxt B. RGD sequence of foot-and-mouth disease virus is essential for infecting cells via the natural receptor but can be bypassed by an antibody-dependent enhancement pathway. Proc Natl Acad Sci USA 1994;91:1932-1936.
40. Jackson T, Ellard FM, Ghazaleh RA, Brookes SM, Blakemore WE, Corteyn AH, Stuart DI, Newman JW, King AM. Efficient infection of cells in culture by type O foot-and-mouth disease virus requires binding to cell surface heparan sulfate. J Virol 1996;70:5282-5287.
41. Fry EE, Lea SM, Jackson T, Newman JW, Ellard FM, Blakemore WE, Abu-Ghazaleh R, Samuel A, King AM, Stuart DI. The structure and function of a foot-and-mouth disease virus-oligosaccharide receptor complex. EMBO J 1999;18:543-554.
42. Triantafilou M, Triantafilou K, Wilson KM, Takada Y, Fernandez N, Stanway G. Involvement of beta2-microglobulin and integrin alphavbeta3 molecules in the coxsackievirus A9 infectious cycle. J Gen Virol 1999;80(Pt 10):2591-2600.
43. Agrez MV, Shafren DR, Gu X, Cox K, Sheppard D, Barry RD. Integrin alpha v beta 6 enhances coxsackievirus B1 lytic infection of human colon cancer cells. Virology 1997;239:71-77.
44. Vlasak M, Goesler I, Blaas D. Human rhinovirus type 89 variants use heparan sulfate proteoglycan for cell attachment. J Virol 2005;79:5963-5970.
45. Reddi HV, Lipton HL. Heparan sulfate mediates infection of high-neurovirulence Theiler's viruses. J Virol 2002;76:8400-8407.
46. Zautner AE, Korner U, Henke A, Badorff C, Schmidtke M. Heparan sulfates and coxsackievirus-adenovirus receptor: Each one mediates coxsackievirus B3 PD infection. J Virol 2003;77:10071-10077.
47. Zautner AE, Jahn B, Hammerschmidt E, Wutzler P, Schmidtke M. N- and 6-O-sulfated heparan sulfates mediate internalization of coxsackievirus B3 variant PD into CHO-K1 cells. J Virol 2006;80:6629-6636.
48. Hafenstein S, Bowman VD, Chipman PR, Bator Kelly CM, Lin F, Medof ME, Rossmann MG. Interaction of decay-accelerating factor with coxsackievirus B3. J Virol 2007;81:12927-12935.
49. Bergelson JM, Mohanty JG, Crowell RL, St JohnNF, Lublin DM, Finberg RW. Coxsackievirus B3 adapted to growth in RD cells binds to decay-accelerating factor (CD55). J Virol 1995;69:1903-1906.
50. Shafren DR, Bates RC, Agrez MV, Herd RL, Burns GF, Barry RD. Coxsackieviruses B1, B3, and B5 use decay accelerating factor as a receptor for cell attachment. J Virol 1995;69:3873-3877.
51. Diana GD, Salvador UJ, Zalay ES, Johnson RE, Collins JC, Johnson D, Hinshaw WB, Lorenz RR, Thielking WH, Pancic F. Antiviral activity of some beta-diketones. 1. Aryl alkyl diketones. In vitro activity against both RNA and DNA viruses. J Med Chem 1977;20:750-756.
52. Diana GD, Salvador UJ, Zalay ES, Carabateas PM, Williams GL, Collins JC, Pancic F. Antiviral activity of some beta-diketones. 2. Aryloxy alkyl diketones. In vitro activity against both RNA and DNA viruses. J Med Chem 1977;20:757-761.
53. Diana GD, Carabateas PM, Salvador UJ, Williams GL, Zalay ES, Pancic F, Steinberg BA, Collins JC. Antiviral activity of some beta-diketones. 3. Aryl bis(beta-diketones). Antiherpetic activity. J Med Chem 1978;21:689-692.
54. Diana GD, Carabateas PM, Johnson RE, Williams GL, Pancic F, Collins JC. Antiviral activity of some beta-diketones. 4. Benzyl diketones. In vitro activity against both RNA and DNA viruses. J Med Chem 1978;21:889-894.
55. McSharry JJ, Caliguiri LA, Eggers HJ. Inhibition of uncoating of poliovirus by arildone, a new antiviral drug. Virology 1979;97:307-315.
56. Caliguiri LA, McSharry JJ, Lawrence GW. Effect of arildone on modifications of poliovirus in vitro. Virology 1980;105:86-93.
57. McKinlay MA, Miralles JV, Brisson CJ, Pancic F. Prevention of human poliovirus-induced paralysis and death in mice by the novel antiviral agent arildone. Antimicrob Agents Chemother 1982;22:1022-1025.
58. Diana GD, McKinlay MA, Otto MJ, Akullian V, Oglesby C. (4,5-Dihydro-2-oxazolyl)phenoxyalkylisoxazoles. Inhibitors of picornavirus uncoating. J Med Chem 1985;28:1906-1910.
59. McKinlay MA. WIN 51711, a new systematically active broad-spectrum antipicornavirus agent. J Antimicrob Chemother 1985;16:284-286.
60. Diana GD, McKinlay MA, Brisson CJ, Zalay ES, Miralles JV, Salvador UJ. Isoxazoles with antipicornavirus activity. J Med Chem 1985;28:748-752.
61. Otto MJ, Fox MP, Fancher MJ, Kuhrt MF, Diana GD, McKinlay MA. In vitro activity of WIN51711, a new broad-spectrum antipicornavirus drug. Antimicrob Agents Chemother 1985;27:883-886.
62. McKinlay MA, Frank JA, Jr., Benziger DP, Steinberg BA. Use of WIN 51711 to prevent echovirus type 9-induced paralysis in suckling mice. J Infect Dis 1986;154:676-681.
63. McKinlay MA, Steinberg BA. Oral efficacy of WIN 51711 in mice infected with human poliovirus. Antimicrob Agents Chemother 1986;29:30-32.
64. Jubelt B, Wilson AK, Ropka SL, Guidinger PL, McKinlay MA. Clearance of a persistent human enterovirus infection of the mouse central nervous system by the antiviral agent disoxaril. J Infect Dis 1989;159:866-871.
65. Nikolaeva-Glomb L, Galabov AS. Synergistic drug combinations against the in vitro replication of Coxsackie B1 virus. Antiviral Res 2004;62:9-19.
66. Nikolaeva L, Galabov AS. Synergistic inhibitory effect of enviroxime and disoxaril on poliovirus type 1 replication. Acta Virol 1995;39:235-241.
67. Nikolaeva L, Galabov AS. In vitro inhibitory effects of dual combinations of picornavirus replication inhibitors. Acta Virol 1999;43:303-311.
68. Nikolaeva L, Galabov AS. Antiviral effect of the combination of enviroxime and disoxaril on coxsackievirus B1 infection. Acta Virol 2000;44:73-78.
69. Fox MP, Otto MJ, McKinlay MA. Prevention of rhinovirus and poliovirus uncoating by WIN 51711, a new antiviral drug. Antimicrob Agents Chemother 1986;30:110-116.
70. Zeichhardt H, Otto MJ, McKinlay MA, Willingmann P, Habermehl KO. Inhibition of poliovirus uncoating by disoxaril (WIN 51711). Virology 1987;160:281-285.
71. Mosser AG, Rueckert RR. WIN 51711-dependent mutants of poliovirus type 3: Evidence that virions decay after release from cells unless drug is present. J Virol 1993;67:1246-1254.
72. Mosser AG, Sgro JY, Rueckert RR. Distribution of drug resistance mutations in type 3 poliovirus identifies three regions involved in uncoating functions. J Virol 1994;68:8193-8201.
73. Woods MG, Diana GD, Rogge MC, Otto MJ, Dutko FJ, McKinlay MA. In vitro and in vivo activities of WIN 54954, a new broad-spectrum antipicornavirus drug. Antimicrob Agents Chemother 1989;33:2069-2074.
74. See DM, Tilles JG. WIN 54954 treatment of mice infected with a diabetogenic strain of group B coxsackievirus. Antimicrob Agents Chemother 1993;37:1593-1598.
75. See DM, Tilles JG. Treatment of Coxsackievirus A9 myocarditis in mice with WIN 54954. Antimicrob Agents Chemother 1992;36:425-428.
76. Turner RB, Dutko FJ, Goldstein NH, Lockwood G, Hayden FG. Efficacy of oral WIN 54954 for prophylaxis of experimental rhinovirus infection. Antimicrob Agents Chemother 1993;37:297-300.
77. Diana GD, Rudewicz P, Pevear DC, Nitz TJ, Aldous SC, Aldous DJ, Robinson DT, Draper T, Dutko FJ, Aldi C. Picornavirus inhibitors: Trifluoromethyl substitution provides a global protective effect against hepatic metabolism. J Med Chem 1995;38:1355-1371.
78. Pevear DC, Tull TM, Seipel ME, Groarke JM. Activity of pleconaril against enteroviruses. Antimicrob Agents Chemother 1999;43:2109-2115.
79. Florea NR, Maglio D, Nicolau DP. Pleconaril, a novel antipicornaviral agent. Pharmacotherapy 2003;23:339-348.
80. Kearns GL, Bradley JS, Jacobs RF, Capparelli EV, James LP, Johnson KM, Abdel-Rahman SM. Single dose pharmacokinetics of pleconaril in neonates. Pediatric Pharmacology Research Unit Network. Pediatr Infect Dis J 2000;19:833-839.
81. Aradottir E, Alonso EM, Shulman ST. Severe neonatal enteroviral hepatitis treated with pleconaril. Pediatr Infect Dis J 2001;20:457-459.
82. Rotbart HA, Webster AD. Treatment of potentially life-threatening enterovirus infections with pleconaril. Clin Infect Dis 2001;32:228-235.
83. Abzug MJ, Cloud G, Bradley J, Sanchez PJ, Romero J, Powell D, Lepow M, Mani C, Capparelli EV, Blount S, Lakeman F, Whitley RJ, Kimberlin DW. Double blind placebo-controlled trial of pleconaril in infants with enterovirus meningitis. Pediatr Infect Dis J 2003;22:335-341.
84. Hayden FG, Herrington DT, Coats TL, Kim K, Cooper EC, Villano SA, Liu S, Hudson S, Pevear DC, Collett M, McKinlay M. Efficacy and safety of oral pleconaril for treatment of colds due to picornaviruses in adults: Results of 2 double-blind, randomized, placebo-controlled trials. Clin Infect Dis 2003;36:1523-1532.
85. Pevear DC, Hayden FG, Demenczuk TM, Barone LR, McKinlay MA, Collett MS. Relationship of pleconaril susceptibility and clinical outcomes in treatment of common colds caused by rhinoviruses. Antimicrob Agents Chemother 2005;49:4492-4499.
86. Senior K. FDA panel rejects common cold treatment. Lancet Infect Dis 2002;2:264.
87. Rossmann MG, Reuckert RR. What does the molecular structure of viruses tell us about viral functions? Microbiol Sci 1987;4:206-214.
88. Badger J, Minor I, Oliveira MA, Smith TJ, Rossmann MG. Structural analysis of antiviral agents that interact with the capsid of human rhinoviruses. Proteins 1989;6:1-19.
89. Badger J, Minor I, Kremer MJ, Oliveira MA, Smith TJ, Griffith JP, Guerin DM, Krishnaswamy S, Luo M, Rossmann MG. Structural analysis of a series of antiviral agents complexed with human rhinovirus 14. Proc Natl Acad Sci USA 1988;85:3304-3308.
90. Rossmann MG. The structure of antiviral agents that inhibit uncoating when complexed with viral capsids. Antiviral Res 1989;11:3-13.
91. Smith TJ, Kremer MJ, Luo M, Vriend G, Arnold E, Kamer G, Rossmann MG, McKinlay MA, Diana GD, Otto MJ. The site of attachment in human rhinovirus 14 for antiviral agents that inhibit uncoating. Science 1986;233:1286-1293.
92. Pevear DC, Fancher MJ, Felock PJ, Rossmann MG, Miller MS, Diana G, Treasurywala AM, McKinlay MA, Dutko FJ. Conformational change in the floor of the human rhinovirus canyon blocks adsorption to HeLa cell receptors. J Virol 1989;63:2002-2007.
93. Zhao R, Pevear DC, Kremer MJ, Giranda VL, Kofron JA, Kuhn RJ, Rossmann MG. Human rhinovirus 3 at 3.0 A resolution. Structure 1996;4:1205-1220.
94. Kim KH, Willingmann P, Gong ZX, Kremer MJ, Chapman MS, Minor I, Oliveira MA, Rossmann MG, Andries K, Diana GD. A comparison of the anti-rhinoviral drug binding pocket in HRV14 and HRV1A. J Mol Biol 1993;230:206-227.
95. Kim SS, Smith TJ, Chapman MS, Rossmann MC, Pevear DC, Dutko FJ, Felock PJ, Diana GD, McKinlay MA. Crystal structure of human rhinovirus serotype 1A (HRV1A). J Mol Biol 1989;210:91-111.
96. Vaidehi N, Goddard WA III. The pentamer channel stiffening model for drug action on human rhinovirus HRV-1A. Proc Natl Acad Sci USA 1997;94:2466-2471.
97. Bibler-Muckelbauer JK, Kremer MJ, Rossmann MG, Diana GD, Dutko FJ, Pevear DC, McKinlay MA. Human rhinovirus 14 complexed with fragments of active antiviral compounds. Virology 1994;202:360-369.
98. Oliveira MA, Zhao R, Lee WM, Kremer MJ, Minor I, Rueckert RR, Diana GD, Pevear DC, Dutko FJ, McKinlay MA. The structure of human rhinovirus 16. Structure 1993;1:51-68.
99. Hadfield AT, Diana GD, Rossmann MG. Analysis of three structurally related antiviral compounds in complex with human rhinovirus 16. Proc Natl Acad Sci USA 1999;96:14730-14735.
100. Badger J, Krishnaswamy S, Kremer MJ, Oliveira MA, Rossmann MG, Heinz BA, Rueckert RR, Dutko FJ, McKinlay MA. Three-dimensional structures of drug-resistant mutants of human rhinovirus 14. J Mol Biol 1989;207:163-174.
101. Groarke JM, Pevear DC. Attenuated virulence of pleconaril-resistant coxsackievirus B3 variants. J Infect Dis 1999;179:1538-1541.
102. Hadfield AT, Oliveira MA, Kim KH, Minor I, Kremer MJ, Heinz BA, Shepard D, Pevear DC, Rueckert RR, Rossmann MG. Structural studies on human rhinovirus 14 drug-resistant compensation mutants. J Mol Biol 1995;253:61-73.
103. Heinz BA, Rueckert RR, Shepard DA, Dutko FJ, McKinlay MA, Fancher M, Rossmann MG, Badger J, Smith TJ. Genetic and molecular analyses of spontaneous mutants of human rhinovirus 14 that are resistant to an antiviral compound. J Virol 1989;63:2476-2485.
104. Lee WM, Wang W. Human rhinovirus type 16: Mutant V1210A requires capsid-binding drug for assembly of pentamers to form virions during morphogenesis. J Virol 2003;77:6235-6244.
105. Wang W, Lee WM, Mosser AG, Rueckert RR. WIN 52035-dependent human rhinovirus 16: Assembly deficiency caused by mutations near the canyon surface. J Virol 1998;72:1210-1218.
106. Schmidtke M, Hammerschmidt E, Schuler S, Zell R, Birch-Hirschfeld E, Makarov VA, Riabova OB, Wutzler P. Susceptibility of coxsackievirus B3 laboratory strains and clinical isolates to the capsid function inhibitor pleconaril: Antiviral studies with virus chimeras demonstrate the crucial role of amino acid 1092 in treatment. J Antimicrob Chemother 2005;56:648-656.
107. Ledford RM, Collett MS, Pevear DC. Insights into the genetic basis for natural phenotypic resistance of human rhinoviruses to pleconaril. Antiviral Res 2005;68:135-138.
108. Andries K, Dewindt B, Snoeks J, Wouters L, Moereels H, Lewi PJ, Janssen PA. Two groups of rhinoviruses revealed by a panel of antiviral compounds present sequence divergence and differential pathogenicity. J Virol 1990;64:1117-1123.
109. Andries K, Dewindt B, Snoeks J, Willebrords R, Stokbroekx R, Lewi PJ. A comparative test of fifteen compounds against all known human rhinovirus serotypes as a basis for a more rational screening program. Antiviral Res 1991;16:213-225.
110. Ledford RM, Patel NR, Demenczuk TM, Watanyar A, Herbertz T, Collett MS, Pevear DC. VP1 sequencing of all human rhinovirus serotypes: Insights into genus phylogeny and susceptibility to antiviral capsid-binding compounds. J Virol 2004;78:3663-3674.
111. Andries K, Dewindt B, De Brabander M, Stokbroekx R, Janssen PA. In vitro activity of R 61837, a new antirhinovirus compound. Arch Virol 1988;101:155-167.
112. Andries K, Dewindt B, Snoeks J, Willebrords R, van Eemeren K, Stokbroekx R, Janssen PA. In vitro activity of pirodavir (R 77975), a substituted phenoxy-pyridazinamine with broad-spectrum antipicornaviral activity. Antimicrob Agents Chemother 1992;36:100-107.
113. Andries K, Dewindt B, Snoeks J, Willebrords R. Lack of quantitative correlation between inhibition of replication of rhinoviruses by an antiviral drug and their stabilization. Arch Virol 1989;106:51-61.
114. Moeremans M, De Raeymaeker M, Daneels G, De Brabander M, Aerts F, Janssen C, Andries K. Study of the parameters of binding of R 61837 to human rhinovirus 9 and immunobiochemical evidence of capsid-stabilizing activity of the compound. Antimicrob Agents Chemother 1992;36:417-424.
115. Chapman MS, Minor I, Rossmann MG, Diana GD, Andries K. Human rhinovirus 14 complexed with antiviral compound R 61837. J Mol Biol 1991;217:455-463.
116. al Nakib W, Higgins PG, Barrow GI, Tyrrell DA, Andries K, Vanden Bussche G, Taylor N, Janssen PA. Suppression of colds in human volunteers challenged with rhinovirus by a new synthetic drug (R61837). Antimicrob Agents Chemother 1989;33:522-525.
117. Hayden FG, Andries K, Janssen PA. Safety and efficacy of intranasal pirodavir (R77975) in experimental rhinovirus infection. Antimicrob Agents Chemother 1992;36:727-732.
118. Hayden FG, Hipskind GJ, Woerner DH, Eisen GF, Janssens M, Janssen PA, Andries K. Intranasal pirodavir (R77,975) treatment of rhinovirus colds. Antimicrob Agents Chemother 1995;39:290-294.
119. Watson KG, Brown RN, Cameron R, Chalmers DK, Hamilton S, Jin B, Krippner GY, Luttick A, McConnell DB, Reece PA, Ryan J, Stanislawski PC, Tucker SP, Wu WY, Barnard DL, Sidwell RW. An orally bioavailable oxime ether capsid binder with potent activity against human rhinovirus. J Med Chem 2003;46:3181-3184.
120. Barnard DL, Hubbard VD, Smee DF, Sidwell RW, Watson KG, Tucker SP, Reece PA. In vitro activity of expanded-spectrum pyridazinyl oxime ethers related to pirodavir: Novel capsid-binding inhibitors with potent antipicornavirus activity. Antimicrob Agents Chemother 2004;48:1766-1772.
121. Brown RN, Cameron R, Chalmers DK, Hamilton S, Luttick A, Krippner GY, McConnell DB, Nearn R, Stanislawski PC, Tucker SP, Watson KG. 2-Ethoxybenzoxazole as a bioisosteric replacement of an ethyl benzoate group in a human rhinovirus (HRV) capsid binder. Bioorg Med Chem Lett 2005;15:2051-2055.
122. Makarov VA, Riabova OB, Granik VG, Wutzler P, Schmidtke M. Novel, (biphenyloxy)propylisoxazole derivatives for inhibition of human rhinovirus 2 and coxsackievirus B3 replication. J Antimicrob Chemother 2005;55:483-488.
123. Kuz'min VE, Artemenko AG, Muratov EN, Volineckaya IL, Makarov VA, Riabova OB, Wutzler P, Schmidtke M. Quantitative structure-activity relationship studies of (biphenyloxy)propylisoxazole derivatives. Inhibitors of human rhinovirus 2 replication. J Med Chem 2007;50:4205-4213.
124. Shia KS, Li WT, Chang CM, Hsu MC, Chern JH, Leong MK, Tseng SN, Lee CC, Lee YC, Chen SJ, Peng KC, Tseng HY, Chang YL, Tai CL, Shih SR. Design, synthesis, and structure-activity relationship of pyridyl imidazolidinones: A novel class of potent and selective human enterovirus 71 inhibitors. J Med Chem 2002;45:1644-1655.
125. Shih SR, Tsai MC, Tseng SN, Won KF, Shia KS, Li WT, Chern JH, Chen GW, Lee CC, Lee YC, Peng KC, Chao YS. Mutation in enterovirus 71 capsid protein VP1 confers resistance to the inhibitory effects of pyridyl imidazolidinone. Antimicrob Agents Chemother 2004;48:3523-3529.
126. Chang CS, Lin YT, Shih SR, Lee CC, Lee YC, Tai CL, Tseng SN, Chern JH. Design, synthesis, and antipicornavirus activity of 1-5-(4-arylphenoxy)alkyl-3- pyridin-4-ylimidazolidin-2-one derivatives. J Med Chem 2005;48:3522-3535.
127. Chern JH, Lee CC, Chang CS, Lee YC, Tai CL, Lin YT, Shia KS, Lee CY, Shih SR. Synthesis and antienteroviral activity of a series of novel, oxime ether-containing pyridyl imidazolidinones. Bioorg Med Chem Lett 2004;14:5051-5056.
128. Chern JH, Chang CS, Tai CL, Lee YC, Lee CC, Kang IJ, Lee CY, Shih SR. Synthesis and antipicornavirus activity of (R)- and (S)-1-5-(4′- chlorobiphenyl-4-yloxy)-3-methylpentyl-3-pyridin-4-yl-imidaz olidin-2-one. Bioorg Med Chem Lett 2005;15:4206-4211.
129. Rozhon E, Cox S, Buontempo P, O'Connell J, Slater W, De Martino J, Schwartz J, Miller G, Arnold E, Zhang A. SCH 38057: A picornavirus capsid-binding molecule with antiviral activity after the initial stage of viral uncoating. Antiviral Res 1993;21:15-35.
130. Zhang A, Nanni RG, Li T, Arnold GF, Oren DA, Jacobo-Molina A, Williams RL, Kamer G, Rubenstein DA, Li Y. Structure determination of antiviral compound SCH 38057 complexed with human rhinovirus 14. J Mol Biol 1993;230:857-867.
131. Cox S, Buontempo PJ, Wright-Minogue J, DeMartino JL, Skelton AM, Ferrari E, Schwartz J, Rozhon EJ, Linn CC, Girijavallabhan V, O'Connell JF. Antipicornavirus activity of SCH 47802 and analogs: In vitro and in vivo studies. Antiviral Res 1996;32:71-79.
132. Buontempo PJ, Cox S, Wright-Minogue J, DeMartino JL, Skelton AM, Ferrari E, Albin R, Rozhon EJ, Girijavallabhan V, Modlin JF, O'Connell JF. SCH 48973: A potent, broad-spectrum, antienterovirus compound. Antimicrob Agents Chemother 1997;41:1220-1225.
133. Lentz KN, Smith AD, Geisler SC, Cox S, Buontempo P, Skelton A, DeMartino J, Rozhon E, Schwartz J, Girijavallabhan V, O'Connell J, Arnold E. Structure of poliovirus type 2 Lansing complexed with antiviral agent SC H48973: Comparison of the structural and biological properties of three poliovirus serotypes. Structure 1997;5:961-978.
134. Rosenwirth B, Oren DA, Arnold E, Kis ZL, Eggers HJ. SDZ 35-682, a new picornavirus capsid-binding agent with potent antiviral activity. Antiviral Res 1995;26:65-82.
135. Rosenwirth B, Kis ZL, Eggers HJ. In vivo efficacy of SDZ 35-682, a new picornavirus capsid-binding agent. Antiviral Res 1995;26:55-64.
136. Oren DA, Zhang A, Nesvadba H, Rosenwirth B, Arnold E. Synthesis and activity of piperazine-containing antirhinoviral agents and crystal structure of SDZ 880-061bound to human rhinovirus 14. J Mol Biol 1996;259:120-134.
137. Ishitsuka H, Ninomiya YT, Ohsawa C, Fujiu M, Suhara Y. Direct and specific inactivation of rhinovirus by chalcone Ro 09-0410. Antimicrob Agents Chemother 1982;22:617-621.
138. Ninomiya Y, Shimma N, Ishitsuka H. Comparative studies on the antirhinovirus activity and the mode of action of the rhinovirus capsid binding agents, chalcone amides. Antiviral Res 1990;13:61-74.
139. Ninomiya Y, Ohsawa C, Aoyama M, Umeda I, Suhara Y, Ishitsuka H. Antivirus agent, Ro 09-0410, binds to rhinovirus specifically and stabilizes the virus conformation. Virology 1984;134:269-276.
140. Phillpotts RJ, Higgins PG, Willman JS, Tyrrell DA, Lenox-Smith I. Evaluation of the antirhinovirus chalcone Ro 09-0415given orally to volunteers. J Antimicrob Chemother 1984;14:403-409.
141. al Nakib W, Higgins PG, Barrow I, Tyrrell DA, Lenox-Smith I, Ishitsuka H. Intranasal chalcone, Ro 09-0410, as prophylaxis against rhinovirus infection in human volunteers. J Antimicrob Chemother 1987;20:887-892.
142. Yasin SR, al Nakib W, Tyrrell DA. Pathogenicity for humans of human rhinovirus type 2 mutants resistant to or dependent on chalcone Ro 09-0410. Antimicrob Agents Chemother 1990;34:963-966.
143. Bauer DJ, Selway JW, Batchelor JF, Tisdale M, Caldwell IC, Young DA. 40,6-Dichloroflavan (BW683C), a new anti-rhinovirus compound. Nature 1981;292:369-370.
144. Tisdale M, Selway JW. Inhibition of an early stage of rhinovirus replication by dichloroflavan (BW683C). J Gen Virol 1983;64(Pt 4):795-803.
145. Tisdale M, Selway JW. Effect of dichloroflavan (BW683C) on the stability and uncoating of rhinovirus type 1B. J Antimicrob Chemother 1984;14 (Suppl A):97-105.
146. al Nakib W, Willman J, Higgins PG, Tyrrell DA, Shepherd WM, Freestone DS. Failure of intranasally administered 40, 6-dichloroflavan to protect against rhinovirus infection in man. Arch Virol 1987;92:255-260.
147. Phillpotts RJ, Wallace J, Tyrrell DA, Freestone DS, Shepherd WM. Failure of oral 40,6-dichloroflavan to protect against rhinovirus infection in man. Arch Virol 1983;75:115-121.
148. Conti C, Orsi N, Stein ML. Effect of isoflavans and isoflavenes on rhinovirus 1B and its replication in HeLa cells. Antiviral Res 1988;10:117-127.
149. Conti C, Genovese D, Santoro R, Stein ML, Orsi N, Fiore L. Activities and mechanisms of action of halogen-substituted flavanoids against poliovirus type 2 infection in vitro. Antimicrob Agents Chemother 1990;34:460-466.
150. Genovese D, Conti C, Tomao P, Desideri N, Stein ML, Catone S, Fiore L. Effect of chloro-, cyano-, and amidino-substituted flavanoids on enterovirus infection in vitro. Antiviral Res 1995;27:123-136.
151. Conti C, Tomao P, Genovese D, Desideri N, Stein ML, Orsi N. Mechanism of action of the antirhinovirus flavanoid 40,6-dicyanoflavan. Antimicrob Agents Chemother 1992;36:95-99.
152. Genovese D, Catone S, Farah ME, Gambacorta A, Fiore L. Isolation and biological characterization of 3(2H)-isoflavene-resistant and -dependent poliovirus type 2 Sabin mutants. J Gen Virol 1999;80( Pt 1):157-167.
153. Salvati AL, De Dominicis A, Tait S, Canitano A, Lahm A, Fiore L. Mechanism of action at the molecular level of the antiviral drug 3(2H)-isoflavene against type 2 poliovirus. Antimicrob Agents Chemother 2004;48:2233-2243.
154. Eggers HJ, Koch MA, Furst A, Daves GD, Jr., Wilczynski JJ, Folkers K. Rhodanine: A selective inhibitor of the multiplication of echovirus 12. Science 1970;167:294-297.
155. Eggers HJ. Selective inhibition of uncoating of echovirus 12 by rhodanine. A study on early virus-cell interactions. Virology 1977;78:241-252.
156. Rosenwirth B, Eggers HJ. Early processes of echovirus 12-infection: Elution, penetration, and uncoating under the influence of rhodanine. Virology 1979;97:241-255.
157. Rosenwirth B, Eggers HJ. Echovirus 12-induced host cell shutoff is prevented by rhodanine. Nature 1977;267:370-371.
158. Kraus W, Zimmermann H, Zimmermann A, Eggers HJ, Nelsen-Salz B. Infectious cDNA clones of echovirus 12 and a variant resistant against the uncoating inhibitor rhodanine differ in seven amino acids. J Virol 1995;69:5853-5858.
159. Kraus W, Zimmermann H, Eggers HJ, Nelsen-Salz B. Rhodanine resistance and dependence of echovirus 12: A possible consequence of capsid flexibility. J Virol 1997;71:1697-1702.
160. Zerial A, Werner GH, Phillpotts RJ, Willmann JS, Higgins PG, Tyrrell DA. Studies on 44 081 R.P., a new antirhinovirus compound, in cell cultures and in volunteers. Antimicrob Agents Chemother 1985;27:846-850.
161. Alarcon B, Zerial A, Dupiol C, Carrasco L. Antirhinovirus compound 44,081 R.P. inhibits virus uncoating. Antimicrob Agents Chemother 1986;30:31-34.
162. Murray MA, Babe LM. Inhibitory effect of dibenzofuran and dibenzosuberol derivatives on rhinovirus replication in vitro; effective prevention of viral entry by dibenzosuberenone. Antiviral Res 1999;44:123-131.
163. Kenny MT, Dulworth JK, Bargar TM, Torney HL, Graham MC, Manelli AM. In vitro antiviral activity of the 6-substituted 2-(3′,4′- dichlorophenoxy)-2H-pyrano2,3-bpyridines MDL 20,610, MDL 20,646, and MDL 20,957. Antimicrob Agents Chemother 1986;30:516-518.
164. Bargar TM, Dulworth JK, Kenny MT, Massad R, Daniel JK, Wilson T, Sargent RN. 3,4-Dihydro-2-phenyl-2H-pyrano2,3-bpyridines with potent antirhinovirus activity. J Med Chem 1986;29:1590-1595.
165. Kenny MT, Torney HL, Dulworth JK. Mechanism of action of the antiviral compound MDL 20,610. Antiviral Res 1988;9:249-261.
166. Markley LD, Tong YC, Dulworth JK, Steward DL, Goralski CT, Johnston H, Wood SG, Vinogradoff AP, Bargar TM. Antipicornavirus activity of substituted phenoxybenzenes and phenoxypyridines. J Med Chem 1986;29:427-433.
167. Powers RD, Gwaltney JM, Jr., Hayden FG. Activity of 2-(3,4- dichlorophenoxy)-5-nitrobenzonitrile (MDL-860) against picornaviruses in vitro. Antimicrob Agents Chemother 1982;22:639-642.
168. Padalko E, Verbeken E, De Clercq E, Neyts J. Inhibition of coxsackie B3 virus induced myocarditis in mice by 2-(3,4-dichlorophenoxy)-5- nitrobenzonitrile. J Med Virol 2004;72:263-267.
169. Kenny MT, Dulworth JK, Bargar TM, Daniel JK. Antipicornavirus activity of some diaryl methanes and aralkylaminopyridines. Antiviral Res 1987;7:87-97.
170. Torney HL, Dulworth JK, Steward DL. Antiviral activity and mechanism of action of 2-(3,4-dichlorophenoxy)-5-nitrobenzonitrile (MDL-860). Antimicrob Agents Chemother 1982;22:635-638.
171. Kenny MT, Dulworth JK, Torney HL. In vitro and in vivo antipicornavirus activity of some phenoxypyridinecarbonitriles. Antimicrob Agents Chemother 1985;28:745-750.
172. Gonzalez ME, Almela MJ, Yacout M, Carrasco L. 6-(3,4-Dichlorophenoxy)-3- (ethylthio)-2-pyridincarbonitrile inhibits poliovirus uncoating. Antimicrob Agents Chemother 1990;34:1259-1261.
173. Kenny MT, Dulworth JK, Torney HL. In vitro and in vivo anti-picornavirus activity of some p-benzoylphenoxypyridines. Antiviral Res 1986;6:355-367.
174. Caliguiri LA, Tamm I. Action of guanidine on the replication of poliovirus RNA. Virology 1968;35:408-417.
175. Crowther D, Melnick JL. Studies of the inhibitory action of guanidine on poliovirus multiplication in cell cultures. Virology 1961;15:65-74.
176. Loddo B, Ferrari W, Brotzu G, Spanedda A. In vitro inhibition of infectivity of polio viruses by guanidine. Nature 1962;193:97-98.
177. Rightsel WA, Dice JR, McAlpine RJ, Timm EA, McLean IW, Jr., Dixon GJ, Schabel FM, Jr. Antiviral effect of guanidine. Science 1961;134:558-559.
178. Klein M, Hadaschik D, Zimmermann H, Eggers HJ, Nelsen-Salz B. The picornavirus replication inhibitors HBB and guanidine in the echovirus-9 system: The significance of viral protein 2C. J Gen Virol 2000;81:895-901.
179. Siegl G, Eggers HJ. Failure of guanidine and 2-(alpha-hydroxybenzyl) benzimidazole to inhibit replication of hepatitis A virus in vitro. J Gen Virol 1982;61(Pt l):111-114.
180. Pincus SE, Diamond DC, Emini EA, Wimmer E. Guanidine-selected mutants of poliovirus: Mapping of point mutations to polypeptide 2C. J Virol 1986;57:638-646.
181. Herrmann EC, Jr., Herrmann JA, DeLong DC. Prevention of death in mice infected with coxsackievirus A16 using guanidine HCl mixed with substituted benzimidazoles. Antiviral Res 1982;2:339-346.
182. Saunders K, King AM, McCahon D, Newman JW, Slade WR, Forss S. Recombination and oligonucleotide analysis of guanidine-resistant foot-and-mouth disease virus mutants. J Virol 1985;56:921-929.
183. Tershak DR. Inhibition of poliovirus polymerase by guanidine in vitro. J Virol 1982;41:313-318.
184. Barton DJ, Flanegan JB. Synchronous replication of poliovirus RNA: Initiation of negative-strand RNA synthesis requires the guanidine-inhibited activity of protein 2C. J Virol 1997;71:8482-8489.
185. Tolskaya EA, Romanova LI, Kolesnikova MS, Gmyl AP, Gorbalenya AE, Agol VI. Genetic studies on the poliovirus 2C protein, an NTPase. A plausible mechanism of guanidine effect on the 2C function and evidence for the importance of 2C oligomerization. J Mol Biol 1994;236:1310-1323.
186. Saunders K, King AM. Guanidine-resistant mutants of aphthovirus induce the synthesis of an altered nonstructural polypeptide, P34. J Virol 1982;42:389-394.
187. Baltera RF, Jr., Tershak DR. Guanidine-resistant mutants of poliovirus have distinct mutations in peptide 2C. J Virol 1989;63:4441-4444.
188. Pincus SE, Wimmer E. Production of guanidine-resistant and -dependent poliovirus mutants from cloned cDNA: Mutations in polypeptide 2C are directly responsible for altered guanidine sensitivity. J Virol 1986;60:793-796.
189. Pincus SE, Rohl H, Wimmer E. Guanidine-dependent mutants of poliovirus: Identification of three classes with different growth requirements. Virology 1987;157:83-88.
190. Bienz K, Egger D, Troxler M, Pasamontes L. Structural organization of poliovirus RNA replication is mediated by viral proteins of the P2 genomic region. J Virol 1990;64:1156-1163.
191. Pfister T, Wimmer E. Characterization of the nucleoside triphosphatase activity of poliovirus protein 2C reveals a mechanism by which guanidine inhibits poliovirus replication. J Biol Chem 1999;274:6992-7001.
192. Rodriguez PL, Carrasco L. Poliovirus protein 2C has ATPase and GTPase activities. J Biol Chem 1993;268:8105-8110.
193. Eggers HJ, Tamm I. On the mechanism of a selective inhibition of enterovirus multiplication by 2-(alpha-hydroxybenzyl)-benzimidazole. Virology 1962;18:426-438.
194. Eggers HJ, Tamm I. Spectrum and characteristics of the virus inhibitory action of 2-(alphahydroxybenzyl)-benzimidazole. J Exp Med 1961;113:657-682.
195. Eggers HJ, Tamm I. Inhibition of Enterovirus ribonucleic acid synthesis by 2-(alpha-hydroxy-benzyl)-benzimidazole. Nature 1963;197:1327-1328.
196. Hadaschik D, Klein M, Zimmermann H, Eggers HJ, Nelsen-Salz B. Dependence of echovirus 9 on the enterovirus RNA replication inhibitor 2-(alpha- Hydroxybenzyl)-benzimidazole maps to nonstructural protein 2C. J Virol 1999;73:10536-10539.
197. Eggers HJ. Successful treatment of enterovirus-infected mice by 2-(alpha-hydroxybenzyl)-benzimidazole and guanidine. J Exp Med 1976;143:1367-1381.
198. Shimizu H, Agoh M, Agoh Y, Yoshida H, Yoshii K, Yoneyama T, Hagiwara A, Miyamura T. Mutations in the 2C region of poliovirus responsible for altered sensitivity to benzimidazole derivatives. J Virol 2000;74:4146-4154.
199. De Palma AM, Heggermont W, Leyssen P, Purstinger G, Wimmer E, De Clercq E, Rao A, Monforte AM, Chimirri A, Neyts J. Anti-enterovirus activity and structure-activity relationship of a series of 2,6-dihalophenyl-substituted 1H,3H-thiazolo3,4-abenzimidazoles. Biochem Biophys Res Commun 2007;353:628-632.
200. DeLong DC, Reed SE. Inhibition of rhinovirus replication in organ culture by a potential antiviral drug. J Infect Dis 1980;141:87-91.
201. Langford MP, Ball WA, Ganley JP. Inhibition of the enteroviruses that cause acute hemorrhagic conjunctivitis (AHC) by benzimidazoles; enviroxime (LY122772) and enviradone (LY127123). Antiviral Res 1995;27:355-365.
202. Wikel JH, Paget CJ, DeLong DC, Nelson JD, Wu CY, Paschal JW, Dinner A, Templeton RJ, Chaney MO, Jones ND, Chamberlin JW. Synthesis of syn and anti isomers of 6-(hydroxyimino)phenylmethyl-1-(1-methylethyl)sulfonyl-1H-benzimidaz ol-2-amine. Inhibitors of rhinovirus multiplication. J Med Chem 1980;23:368-372.
203. Phillpotts RJ, Jones RW, DeLong DC, Reed SE, Wallace J, Tyrrell DA. The activity of enviroxime against rhinovirus infection in man. Lancet 1981;1:1342-1344.
204. Phillpotts RJ, Wallace J, Tyrrell DA, Tagart VB. Therapeutic activity of enviroxime against rhinovirus infection in volunteers. Antimicrob Agents Chemother 1983;23:671-675.
205. Hayden FG, Gwaltney JM, Jr. Prophylactic activity of intranasal enviroxime against experimentally induced rhinovirus type 39 infection. Antimicrob Agents Chemother 1982;21:892-897.
206. Higgins PG, Barrow GI, al Nakib W, Tyrrell DA, DeLong DC, Lenox-Smith I. Failure to demonstrate synergy between interferon-alpha and a synthetic antiviral, enviroxime, in rhinovirus infections in volunteers. Antiviral Res 1988;10:141-149.
207. Levandowski RA, Pachucki CT, Rubenis M, Jackson GG. Topical enviroxime against rhinovirus infection. Antimicrob Agents Chemother 1982;22:1004-1007.
208. Miller FD, Monto AS, DeLong DC, Exelby A, Bryan ER, Srivastava S. Controlled trial of enviroxime against natural rhinovirus infections in a community. Antimicrob Agents Chemother 1985;27:102-106.
209. Wyde PR, Six HR, Wilson SZ, Gilbert BE, Knight V. Activity against rhinoviruses, toxicity, and delivery in aerosol of enviroxime in liposomes. Antimicrob Agents Chemother 1988;32:890-895.
210. Gilbert BE, Six HR, Wilson SZ, Wyde PR, Knight V. Small particle aerosols of enviroxime-containing liposomes. Antiviral Res 1988;9:355-365.
211. Victor F, Loncharich R, Tang J, Spitzer WA. Synthesis and antiviral activity of C2 analogs of enviroxime: An exploration of the role of critical functionality. J Med Chem 1997;40:3478-3483.
212. Victor F, Brown TJ, Campanale K, Heinz BA, Shipley LA, Su KS, Tang J, Vance LM, Spitzer WA. Synthesis, antiviral activity, and biological properties of vinylacetylene analogs of enviroxime. J Med Chem 1997;40:1511-1518.
213. Hamdouchi C, de Blas J, del Prado M, Gruber J, Heinz BA, Vance L. 2-Amino-3-substituted-6-(E)-1-phenyl-2-(N-methylcarbamoyl)vinylimid azo1,2-apyridines as a novel class of inhibitors of human rhinovirus: Stereospecific synthesis and antiviral activity. J Med Chem 1999;42:50-59.
214. Hamdouchi C, Ezquerra J, Vega JA, Vaquero JJ, Alvarez-Builla J, Heinz BA. Short synthesis and antirhinoviral activity of imidazo1,2-apyridines: The effect of acyl groups at 3-position. Bioorg Med Chem Lett 1999;9:1391-1394.
215. Hamdouchi C, Sanchez-Martinez C, Gruber J, del Prado M, Lopez J, Rubio A, Heinz BA. Imidazo 1,2-bpyridazines, novel nucleus with potent and broad spectrum activity against human picornaviruses: Design, synthesis, and biological evaluation. J Med Chem 2003;46:4333-4341.
216. Ninomiya Y, Aoyama M, Umeda I, Suhara Y, Ishitsuka H. Comparative studies on the modes of action of the antirhinovirus agents Ro 09-0410, Ro 09-0179, RMI-15,731, 40,6-dichloroflavan, and enviroxime. Antimicrob Agents Chemother 1985;27:595-599.
217. Heinz BA, Vance LM. The antiviral compound enviroxime targets the 3A coding region of rhinovirus and poliovirus. J Virol 1995;69:4189-4197.
218. Heinz BA, Vance LM. Sequence determinants of 3A-mediated resistance to enviroxime in rhinoviruses and enteroviruses. J Virol 1996;70:4854-4857.
219. Brown-Augsburger P, Vance LM, Malcolm SK, Hsiung H, Smith DP, Heinz BA. Evidence that enviroxime targets multiple components of the rhinovirus 14 replication complex. Arch Virol 1999;144:1569-1585.
220. Verheyden B, Andries K, Rombaut B. Mode of action of 2-furylmercury chloride, an anti-rhinovirus compound. Antiviral Res 2004;61:189-194.
221. Pinizzotto MR, Garozzo A, Guerrera F, Castro A, La Rosa MG, Furneri PM, Geremia E. In vitro antiviral activity of four isothiazole derivatives against poliovirus type 1. Antiviral Res 1992;19:29-41.
222. Garozzo A, Pinizzotto MR, Guerrera F, Tempera G, Castro A, Geremia E. Antipoliovirus activity of isothiazole derivatives: Mode of action of 5,5′-diphenyl-3,3′-diisothiazole disulfide (DID). Arch Virol 1994;135:1-11.
223. Cutri CC, Garozzo A, Siracusa MA, Castro A, Tempera G, Sarva MC, Guerrera F. Synthesis of new 3-methylthio-5-aryl-4-isothiazolecarbonitriles with broad antiviral spectrum. Antiviral Res 2002;55:357-368.
224. Garozzo A, Cutri CC, Castro A, Tempera G, Guerrera F, Sarva MC, Geremia E. Anti-rhinovirus activity of 3-methylthio-5-aryl-4-isothiazolecarbonitrile derivatives. Antiviral Res 2000;45:199-210.
225. Cushnie TP, Lamb AJ. Antimicrobial activity of flavonoids. Int J Antimicrob Agents 2005;26:343-356.
226. Ishitsuka H, Ohsawa C, Ohiwa T, Umeda I, Suhara Y. Antipicornavirus flavone Ro 09-0179. Antimicrob Agents Chemother 1982;22:611-616.
227. Van Hoof L, Vanden Berghe DA, Hatfield GM, Vlietinck AJ. Plant antiviral agents; V. 3-Methoxyflavones as potent inhibitors of viral-induced block of cell synthesis. Planta Med 1984;50:513-517.
228. Dimova S, Mugabowindekwe R, Willems T, Brewster ME, Noppe M, Ludwig A, Jorissen M, Augustijns P. Safety-assessment of 3-methoxyquercetin as an antirhinoviral compound for nasal application: Effect on ciliary beat frequency. Int J Pharm 2003;263:95-103.
229. De Meyer N, Haemers A, Mishra L, Pandey HK, Pieters LA, Vanden Berghe DA, Vlietinck AJ. 4′-Hydroxy-3-methoxyflavones with potent antipicornavirus activity. J Med Chem 1991;34:736-746.
230. Castrillo JL, Vanden Berghe D, Carrasco L. 3-Methylquercetin is a potent and selective inhibitor of poliovirus RNA synthesis. Virology 1986;152:219-227.
231. Castrillo JL, Carrasco L. Action of 3-methylquercetin on poliovirus RNA replication. J Virol 1987;61:3319-3321.
232. Vrijsen R, Everaert L, Van Hoof LM, Vlietinck AJ, Vanden Berghe DA, Boeye A. The poliovirus-induced shut-off of cellular protein synthesis persists in the presence of 3-methylquercetin, a flavonoid which blocks viral protein and RNA synthesis. Antiviral Res 1987;7:35-42.
233. Vlietinck AJ, Vanden Berghe DA, Van Hoof LM, Vrijsen R, Boeye A. Antiviral activity of 3-methoxyflavones. Prog Clin Biol Res 1986;213:537-540.
234. Lopez Pila JM, Kopecka H, Vanden Berghe D. Lack of evidence for strand-specific inhibition of poliovirus RNA synthesis by 3-methylquercetin. Antiviral Res 1989;11:47-53.
235. Robin V, Irurzun A, Amoros M, Boustie J, Carrasco L. Antipoliovirus flavonoids from Psiadia dentata. Antivir Chem Chemother 2001;12:283-291.
236. Semple SJ, Nobbs SF, Pyke SM, Reynolds GD, Flower RL. Antiviral flavonoid from Pterocaulon sphacelatum, an Australian Aboriginal medicine. J Ethnopharmacol 1999;68:283-288.
237. Conti C, Mastromarino P, Sgro R, Desideri N. Anti-picornavirus activity of synthetic flavon-3-yl esters. Antivir Chem Chemother 1998;9:511-515.
238. Conti C, Mastromarino P, Goldoni P, Portalone G, Desideri N. Synthesis and anti-rhinovirus properties of fluoro-substituted flavonoids. Antivir Chem Chemother 2005;16:267-276.
239. Desideri N, Conti C, Mastromarino P, Mastropaolo F. Synthesis and anti-rhinovirus activity of 2-styrylchromones. Antivir Chem Chemother 2000;11:373-381.
240. Desideri N, Mastromarino P, Conti C. Synthesis and evaluation of antirhinovirus activity of 3-hydroxy and 3-methoxy 2-styrylchromones. Antivir Chem Chemother 2003;14:195-203.
241. Tait S, Salvati AL, Desideri N, Fiore L. Antiviral activity of substituted homoisoflavonoids on enteroviruses. Antiviral Res 2006;72:252-255.
242. Desideri N, Conti C, Sestili I, Tomao P, Stein ML, Orsi N. In vitro evaluation of the anti-picornavirus activities of new synthetic flavonoids. Antivir Chem Chemother 1995;6:298-306.
243. Desideri N, Olivieri S, Stein ML, Sgro R, Orsi N, Conti C. Synthesis and anti-picornavirus activity of homo-isoflavonoids. Antivir Chem Chemother 1997;8:545-555.
244. Larin NM, Copping MP, Herbst-Laier RH, Roberts B, Wenham RB. Antiviral activity of gliotoxin. Chemotherapy 1965;10:12-23.
245. Miller PA, Milstrey KP, Trown PW. Specific inhibition of viral ribonucleic acid replication by Gliotoxin. Science 1968;159:431-432.
246. Trown PW, Bilello JA. Mechanism of action of gliotoxin: Elimination of activity by sulfhydryl compounds. Antimicrob Agents Chemother 1972;2:261-266.
247. Rodriguez PL, Carrasco L. Gliotoxin: Inhibitor of poliovirus RNA synthesis that blocks the viral RNA polymerase 3Dpol. J Virol 1992;66:1971-1976.
248. Goris N, De Palma A, Toussaint JF, Musch I, Neyts J, De Clercq K. 2′-C-Methylcytidine as a potent and selective inhibitor of the replication of foot-and-mouth disease virus. Antiviral Res 2006.
249. Harki DA, Graci JD, Galarraga JE, Chain WJ, Cameron CE, Peterson BR. Synthesis and antiviral activity of 5-substituted cytidine analogues: Identification of a potent inhibitor of viral RNA-dependent RNA polymerases. J Med Chem 2006;49:6166-6169.
250. Gaudernak E, Seipelt J, Triendl A, Grassauer A, Kuechler E. Antiviral effects of pyrrolidine dithiocarbamate on human rhinoviruses. J Virol 2002;76:6004-6015.
251. Krenn BM, Holzer B, Gaudernak E, Triendl A, van Kuppeveld FJ, Seipelt J. Inhibition of polyprotein processing and RNA replication of human rhinovirus by pyrrolidine dithiocarbamate involves metal ions. J Virol 2005;79:13892-13899.
252. Lanke K, Krenn BM, Melchers WJ, Seipelt J, van Kuppeveld FJ. PDTC inhibits picornavirus polyprotein processing and RNA replication by transporting zinc ions into cells. J Gen Virol 2007;88:1206-1217.
253. Si X, McManus BM, Zhang J, Yuan J, Cheung C, Esfandiarei M, Suarez A, Morgan A, Luo H. Pyrrolidine dithiocarbamate reduces coxsackievirus B3 replication through inhibition of the ubiquitin-proteasome pathway. J Virol 2005;79:8014-8023.
254. Kitamura N, Semler BL, Rothberg PG, Larsen GR, Adler CJ, Dorner AJ, Emini EA, Hanecak R, Lee JJ, van der Werf S, Anderson CW, Wimmer E. Primary structure, gene organization and polypeptide expression of poliovirus RNA. Virology 1981;291:547-553.
255. Bazan JF, Fletterick RJ. Viral cysteine proteases are homologous to the trypsin-like family of serine proteases: Structural and functional implications. Proc Natl Acad Sci USA 1988;85:7872-7876.
256. Racaniello VR. Picornaviridae: The viruses and their replication. In Knipe DM, Howley PM, editors. Fields virology. 4th edition. Philadelphia: Lippencott Williams & Wilkens; 2001. pp 685-722.
257. Ryan MD, Flint M. Virus-encoded proteinases of the picornavirus super-group. J Gen Virol 1997;78:699-723.
258. Piccone ME, Zellner M, Kumosinski TF, Mason PW, Grubman MJ. Identification of the active-site residues of the L proteinase of foot-and-mouth disease virus. J Virol 1995;69:4950-4956.
259. Glaser W, Cencic R, Skern T. Foot-and-mouth disease virus leader proteinase: Involvement of C-terminal residues in self-processing and cleavage of eIF4GI. J Biol Chem 2001;276:35473-35481.
260. Guarne A, Tormo J, Kirchweger R, Pfistermueller D, Fita I, Skern T. Structure of the foot-and-mouth disease virus leader protease: A papain-like fold adapted for self-processing and eIF4G recognition. EMBO J 1998;17:7469-7479.
261. Devaney MA, Vakharia VN, Lloyd RE, Ehrenfeld E, Grubman MJ. Leader protein of foot-and-mouth disease virus is required for cleavage of the p220 component of the cap-binding protein complex. J Virol 1988;62:4407-4409.
262. Medina M, Domingo E, Brangwyn JK, Belsham GJ. The two species of the foot-and-mouth disease virus leader protein, expressed individually, exhibit the same activities. Virology 1993;194:355-359.
263. Belsham GJ, Brangwyn JK. A region of the 50 noncoding region of foot-and-mouth disease virus RNA directs efficient internal initiation of protein synthesis within cells: Involvement with the role of L protease in translational control. J Virol 1990;64:5389-5395.
264. Kuhn R, Luz N, Beck E. Functional analysis of the internal translation initiation site of foot-and-mouth disease virus. J Virol 1990;64:4625-4631.
265. Ziegler E, Borman AM, Kirchweger R, Skern T, Kean KM. Foot-and-mouth disease virus Lb proteinase can stimulate rhinovirus and enterovirus IRES-driven translation and cleave several proteins of cellular and viral origin. J Virol 1995;69:3465-3474.
266. Ohlmann T, Rau M, Pain VM, Morley SJ. The C-terminal domain of eukaryotic protein synthesis initiation factor (eIF) 4G is sufficient to support cap-independent translation in the absence of eIF4E. EMBO J 1996;15:1371-1382.
267. Borman AM, Kirchweger R, Ziegler E, Rhoads RE, Skern T, Kean KM. elF4G and its proteolytic cleavage products: Effect on initiation of protein synthesis from capped, uncapped, and IRES-containing mRNAs. RNA 1997;3:186-196.
268. de Los ST, de Avila BS, Weiblen R, Grubman MJ. The leader proteinase of foot-and-mouth disease virus inhibits the induction of beta interferon mRNA and blocks the host innate immune response. J Virol 2006;80:1906-1914.
269. de Los ST, Diaz-San Segundo F, Grubman MJ. Degradation of nuclear factor kappa B during foot-and-mouth disease virus infection. J Virol 2007;81:12803-12815.
270. Palmenberg AC, Parks GD, Hall DJ, Ingraham RH, Seng TW, Pallai PV. Proteolytic processing of the cardioviral P2 region: Primary 2A/2B cleavage in clone-derived precursors. Virology 1992;190:754-762.
271. Sommergruber W, Zorn M, Blaas D, Fessl F, Volkmann P, Maurer-Fogy I, Pallai P, Merluzzi V, Matteo M, Skern T. Polypeptide 2A of human rhinovirus type 2: Identification as a protease and characterization by mutational analysis. Virology 1989;169:68-77.
272. Petersen JF, Cherney MM, Liebig HD, Skern T, Kuechler E, James MN. The structure of the 2A proteinase from a common cold virus:Aproteinase responsible for the shut-off of host-cell protein synthesis. EMBO J 1999;18:5463-5475.
273. Baxter NJ, Roetzer A, Liebig HD, Sedelnikova SE, Hounslow AM, Skern T, Waltho JP. Structure and dynamics of coxsackievirus B4 2A proteinase, an enyzme involved in the etiology of heart disease. J Virol 2006;80:1451-1462.
274. Tong L. Viral proteases. Chem Rev 2002;102:4609-4626.
275. Ali IK, McKendrick L, Morley SJ, Jackson RJ. Truncated initiation factor eIF4G lacking an eIF4E binding site can support capped mRNA translation. EMBO J 2001;20:4233-4242.
276. Belsham GJ, Sonenberg N. RNA-protein interactions in regulation of picornavirus RNA translation. Microbiol Rev 1996;60:499-511.
277. Hambidge SJ, Sarnow P. Translational enhancement of the poliovirus 50 noncoding region mediated by virus-encoded polypeptide 2A. Proc Natl Acad Sci USA 1992;89:10272-10276.
278. Donnelly ML, Gani D, Flint M, Monaghan S, Ryan MD. The cleavage activities of aphthovirus and cardiovirus 2A proteins. J Gen Virol 1997;78(Pt 1):13-21.
279. Donnelly ML, Luke G, Mehrotra A, Li X, Hughes LE, Gani D, Ryan MD. Analysis of the aphthovirus 2A/2B polyprotein 'cleavage' mechanism indicates not a proteolytic reaction, but a novel translational effect: A putative ribosomal 'skip'. J Gen Virol 2001;82:1013-1025.
280. Donnelly ML, Hughes LE, Luke G, Mendoza H, ten Dam E, Gani D, Ryan MD. The 'cleavage' activities of foot-and-mouth disease virus 2A site-directed mutants and naturally occurring '2A-like' sequences. J Gen Virol 2001;82:1027-1041.
281. de Felipe P, Hughes LE, Ryan MD, Brown JD. Co-translational, intraribosomal cleavage of polypeptides by the foot-and-mouth disease virus 2A peptide. J Biol Chem 2003;278:11441-11448.
282. Jia XY, Summers DF, Ehrenfeld E. Primary cleavage of the HAV capsid protein precursor in the middle of the proposed 2A coding region. Virology 1993;193:515-519.
283. Malcolm BA. The picornaviral 3C proteinases: Cysteine nucleophiles in serine proteinase folds. Protein Sci 1995;4:1439-1445.
284. Jore J, De Geus B, Jackson RJ, Pouwels PH, Enger-Valk BE. Poliovirus protein 3CD is the active protease for processing of the precursor protein P1 in vitro. J Gen Virol 1988;69(Pt 7):1627-1636.
285. Matthews DA, Smith WW, Ferre RA, Condon B, Budahazi G, Sisson W, Villafranca JE, Janson CA, McElroy HE, Gribskov CL. Structure of human rhinovirus 3C protease reveals a trypsin-like polypeptide fold, RNA-binding site, and means for cleaving precursor polyprotein. Cell 1994;77:761-771.
286. Allaire M, Chernaia MM, Malcolm BA, James MN. Picornaviral 3C cysteine proteinases have a fold similar to chymotrypsin-like serine proteinases. Nature 1994;369:72-76.
287. Marcotte LL, Wass AB, Gohara DW, Pathak HB, Arnold JJ, Filman DJ, Cameron CE, Hogle JM. Crystal structure of poliovirus 3CD protein: Virally encoded protease and precursor to the RNA-dependent RNA polymerase. J Virol 2007;81:3583-3596.
288. Joachims M, Van Breugel PC, Lloyd RE. Cleavage of poly(A)-binding protein by enterovirus proteases concurrent with inhibition of translation in vitro. J Virol 1999;73:718-727.
289. Zhang B, Morace G, Gauss-Muller V, Kusov Y. Poly(A) binding protein, C-terminally truncated by the hepatitis A virus proteinase 3C, inhibits viral translation. Nucleic Acids Res 2007;35:5975-5984.
290. Kuyumcu-Martinez NM, Van Eden ME, Younan P, Lloyd RE. Cleavage of poly(A)-binding protein by poliovirus 3C protease inhibits host cell translation: A novel mechanism for host translation shutoff. Mol Cell Biol 2004;24:1779-1790.
291. Chau DH, Yuan J, Zhang H, Cheung P, Lim T, Liu Z, Sall A, Yang D. Coxsackievirus B3 proteases 2A and 3C induce apoptotic cell death through mitochondrial injury and cleavage of eIF4GI but not DAP5/p97/N AT1. Apoptosis 2007;12:513-524.
292. Perera R, Daijogo S, Walter BL, Nguyen JH, Semler BL. Cellular protein modification by poliovirus: The two faces of poly(rC)-binding protein. J Virol 2007;81:8919-8932.
293. Back SH, Kim YK, Kim WJ, Cho S, Oh HR, Kim JE, Jang SK. Translation of polioviral mRNA is inhibited by cleavage of polypyrimidine tract-binding proteins executed by polioviral 3C(pro). J Virol 2002;76:2529-2542.
294. Kundu P, Raychaudhuri S, Tsai W, Dasgupta A. Shutoff of RNA polymerase II transcription by poliovirus involves 3C protease-mediated cleavage of the TATA-binding protein at an alternative site: Incomplete shutoff of transcription interferes with efficient viral replication. J Virol 2005;79:9702-9713.
295. Clark ME, Lieberman PM, Berk AJ, Dasgupta A. Direct cleavage of human TATA-binding protein by poliovirus protease 3C in vivo and in vitro. Mol Cell Biol 1993;13:1232-1237.
296. Das S, Dasgupta A. Identification of the cleavage site and determinants required for poliovirus 3CPro-catalyzed cleavage of human TATA-binding transcription factor TBP. J Virol 1993;67:3326-3331.
297. Zaragoza C, Saura M, Padalko EY, Lopez-Rivera E, Lizarbe TR, Lamas S, Lowenstein CJ. Viral protease cleavage of inhibitor of kappaBalpha triggers host cell apoptosis. Proc Natl Acad Sci USA 2006;103:19051-19056.
298. Saura M, Lizarbe TR, Rama-Pacheco C, Lowenstein CJ, Zaragoza C. Inhibitor of NF kappa B alpha is a host sensor of coxsackievirus infection. Cell Cycle 2007;6:503-506.
299. Leong LE, Walker PA, Porter AG. Human rhinovirus-14 protease 3C (3Cpro) binds specifically to the 50-noncoding region of the viral RNA. Evidence that 3Cpro has different domains for the RNA binding and proteolytic activities. J Biol Chem 1993;268:25735-25739.
300. Gamarnik AV, Andino R. Two functional complexes formed by KH domain containing proteins with the 50 noncoding region of poliovirus RNA. RNA 1997;3:882-892.
301. Gamarnik AV, Andino R. Switch from translation to RNA replication in a positive-stranded RNA virus. Genes Dev 1998;12:2293-2304.
302. Gamarnik AV, Andino R. Interactions of viral protein 3CD and poly(rC) binding protein with the 5′ untranslated region of the poliovirus genome. J Virol 2000;74:2219-2226.
303. Bell YC, Semler BL, Ehrenfeld E. Requirements for RNA replication of a poliovirus replicon by coxsackievirus B3 RNA polymerase. J Virol 1999;73:9413-9421.
304. Andino R, Rieckhof GE, Achacoso PL, Baltimore D. Poliovirus RNA synthesis utilizes an RNP complex formed around the 5′-end of viral RNA. EMBO J 1993;12:3587-3598.
305. Andino R, Rieckhof GE, Baltimore D. A functional ribonucleoprotein complex forms around the 5′ end of poliovirus RNA. Cell 1990;63:369-380.
306. Mehdi S. Cell-penetrating inhibitors of calpain. Trends Biochem Sci 1991;16:150-153.
307. Kleina LG, Grubman MJ. Antiviral effects of a thiol protease inhibitor on foot-and-mouth disease virus. J Virol 1992;66:7168-7175.
308. Komatsu K, Inazuki K, Hosoya J, Satoh S. Beneficial effect of new thiol protease inhibitors, epoxide derivatives, on dystrophic mice. Exp Neurol 1986;91:23-29.
309. Kaldor SW, Hammond M, Dressman BA, Labus J, Chadwell F, Kline AD, Heinz BA. Glutamine-derived aldehydes for the inhibition of human rhinovirus 3C protease. Bioorg Med Chem Lett 1995;5:2021-2026.
310. Cordingley MG, Callahan PL, Sardana VV, Garsky VM, Colonno RJ. Substrate requirements of human rhinovirus 3C protease for peptide cleavage in vitro. J Biol Chem 1990;265:9062-9065.
311. Kaldor SW, Hammond M, Dressman BA, Labus J, Chadwell F, Kline AD, Heinz BA. Glutamine-derived aldehydes for the inhibition of human rhinovirus 3C protease. Bioorg Med Chem Lett 2005;5:2021-2026.
312. Shepherd TA, Cox GA, McKinneay E, Tang T, Wakulchick M, Zimmerman RE, Villarreal EC. Small peptidic aldehyde inhibitors of human rhinovirus 3C protease. Bioorg Med Chem Lett 1996;6:2893-2896.
313. Webber SE, Okano K, Little TL, Reich SH, Xin Y, Fuhrman SA, Matthews DA, Love RA, Hendrickson TF, Patick AK, Meador JW III, Ferre RA, Brown EL, Ford CE, Binford SL, Worland ST. Tripeptide aldehyde inhibitors of human rhinovirus 3C protease: Design, synthesis, biological evaluation, and cocrystal structure solution of P1 glutamine isosteric replacements. J Med Chem 1998;41:2786-2805.
314. Dragovich PS, Zhou R, Webber SE, Prins TJ, Kwok AK, Okano K, Fuhrman SA, Zalman LS, Maldonado FC, Brown EL, Meador JW III, Patick AK, Ford CE, Brothers MA, Binford SL, Matthews DA, Ferre RA, Worland ST. Structure-based design of ketone-containing, tripeptidyl human rhinovirus 3C protease inhibitors. Bioorg Med Chem Lett 2000;10:45-48.
315. Malcolm BA, Lowe C, Shechosky S, McKay RT, Yang CC, Shah VJ, Simon RJ, Vederas JC, Santi DV. Peptide aldehyde inhibitors of hepatitis A virus 3C proteinase. Biochemistry 1995;34:8172-8179.
316. Hanzlik RP, Thompson SA. Vinylogous amino acid esters: A new class of inactivators for thiol proteases. J Med Chem 1984;27:711-712.
317. Liu S, Hanzlik RP. Structure-activity relationships for inhibition of papain by peptide Michael acceptors. J Med Chem 1992;35:1067-1075.
318. Kong JS, Venkatraman S, Furness K, Nimkar S, Shepherd TA, Wang QM, Aube J, Hanzlik RP. Synthesis and evaluation of peptidyl Michael acceptors that inactivate human rhinovirus 3C protease and inhibit virus replication. J Med Chem 1998;41:2579-2587.
319. Dragovich PS, Webber SE, Babine RE, Fuhrman SA, Patick AK, Matthews DA, Lee CA, Reich SH, Prins TJ, Marakovits JT, Littlefield ES, Zhou R, Tikhe J, Ford CE, Wallace MB, Meador JW III, Ferre RA, Brown EL, Binford SL, Harr JE, DeLisle DM, Worland ST. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 1. Michael acceptor structure-activity studies. J Med Chem 1998;41:2806-2818.
320. Dragovich PS, Webber SE, Babine RE, Fuhrman SA, Patick AK, Matthews DA, Reich SH, Marakovits JT, Prins TJ, Zhou R, Tikhe J, Littlefield ES, Bleckman TM, Wallace MB, Little TL, Ford CE, Meador JW III, Ferre RA, Brown EL, Binford SL, DeLisle DM, Worland ST. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 2. Peptide structure-activity studies. J Med Chem 1998;41:2819-2834.
321. Dragovich PS, Prins TJ, Zhou R, Webber SE, Marakovits JT, Fuhrman SA, Patick AK, Matthews DA, Lee CA, Ford CE, Burke BJ, Rejto PA, Hendrickson TF, Tuntland T, Brown EL, Meador JW III, Ferre RA, Harr JE, Kosa MB, Worland ST. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 4. Incorporation of P1 lactam moieties as L-glutamine replacements. J Med Chem 1999;42:1213-1224.
322. Dragovich PS, Prins TJ, Zhou R, Fuhrman SA, Patick AK, Matthews DA, Ford CE, Meador JW III, Ferre RA, Worland ST. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 3. Structure-activity studies of ketomethylene-containing peptidomimetics. J Med Chem 1999;42:1203-1212.
323. Dragovich PS, Webber SE, Prins TJ, Zhou R, Marakovits JT, Tikhe JG, Fuhrman SA, Patick AK, Matthews DA, Ford CE, Brown EL, Binford SL, Meador JW III, Ferre RA, Worland ST. Structure-based design of irreversible, tripeptidyl human rhinovirus 3C protease inhibitors containing N-methyl amino acids. Bioorg Med Chem Lett 1999;9:2189-2194.
324. Webber SE, Marakovits JT, Dragovich PS, Prins TJ, Zhou R, Fuhrman SA, Patick AK, Matthews DA, Lee CA, Srinivasan B, Moran T, Ford CE, Brothers MA, Harr JE, Meador JW III, Ferre RA, Worland ST. Design and synthesis of irreversible depsipeptidyl human rhinovirus 3C protease inhibitors. Bioorg Med Chem Lett 2001;11:2683-2686.
325. Matthews DA, Dragovich PS, Webber SE, Fuhrman SA, Patick AK, Zalman LS, Hendrickson TF, Love RA, Prins TJ, Marakovits JT, Zhou R, Tikhe J, Ford CE, Meador JW, Ferre RA, Brown EL, Binford SL, Brothers MA, DeLisle DM, Worland ST. Structure-assisted design of mechanism-based irreversible inhibitors of human rhinovirus 3C protease with potent antiviral activity against multiple rhinovirus serotypes. Proc Natl Acad Sci USA 1999;96:11000-11007.
326. Witherell G. AG-7088 Pfizer. Curr Opin Investig Drugs 2000;1:297-302.
327. Patick AK, Binford SL, Brothers MA, Jackson RL, Ford CE, Diem MD, Maldonado F, Dragovich PS, Zhou R, Prins TJ, Fuhrman SA, Meador JW, Zalman LS, Matthews DA, Worland ST. In vitro antiviral activity of AG7088, a potent inhibitor of human rhinovirus 3C protease. Antimicrob Agents Chemother 1999;43:2444-2450.
328. Binford SL, Maldonado F, Brothers MA, Weady PT, Zalman LS, Meador JW III, Matthews DA, Patick AK. Conservation of amino acids in human rhinovirus 3C protease correlates with broad-spectrum antiviral activity of rupintrivir, a novel human rhinovirus 3C protease inhibitor. Antimicrob Agents Chemother 2005;49:619-626.
329. Kaiser L, Crump CE, Hayden FG. In vitro activity of pleconaril and AG7088 against selected serotypes and clinical isolates of human rhinoviruses. Antiviral Res 2000;47:215-220.
330. Zalman LS, Brothers MA, Dragovich PS, Zhou R, Prins TJ, Worland ST, Patick AK. Inhibition of human rhinovirus-induced cytokine production by AG7088, a human rhinovirus 3C protease inhibitor. Antimicrob Agents Chemother 2000;44:1236-1241.
331. Zhang KE, Hee B, Lee CA, Liang B, Potts BC. Liquid chromatography-mass spectrometry and liquid chromatography-NMR characterization of in vitro metabolites of a potent and irreversible peptidomimetic inhibitor of rhinovirus 3C protease. Drug Metab Dispos 2001;29:729-734.
332. Hsyu PH, Pithavala YK, Gersten M, Penning CA, Kerr BM. Pharmacokinetics and safety of an antirhinoviral agent, ruprintrivir, in healthy volunteers. Antimicrob Agents Chemother 2002;46:392-397.
333. Hayden FG, Turner RB, Gwaltney JM, Chi-Burris K, Gersten M, Hsyu P, Patick AK, Smith GJ III, Zalman LS. Phase II, randomized, double-blind, placebo-controlled studies of ruprintrivir nasal spray 2-percent suspension for prevention and treatment of experimentally induced rhinovirus colds in healthy volunteers. Antimicrob Agents Chemother 2003;47:3907-3916.
334. Patick AK, Brothers MA, Maldonado F, Binford S, Maldonado O, Fuhrman S, Petersen A, Smith GJ III, Zalman LS, Burns-Naas LA, Tran JQ. In vitro antiviral activity and single-dose pharmacokinetics in humans of a novel, orally bioavailable inhibitor of human rhinovirus 3C protease. Antimicrob Agents Chemother 2005;49:2267-2275.
335. Lee ES, Lee WG, Yun SH, Rho SH, Im I, Yang ST, Sellamuthu S, Lee YJ, Kwon SJ, Park OK, Jeon ES, Park WJ, Kim YC. Development of potent inhibitors of the coxsackievirus 3C protease. Biochem Biophys Res Commun 2007;358:7-11.
336. Kati WM, Sham HL, McCall JO, Montgomery DA, Wang GT, Rosenbrook W, Miesbauer L, Buko A, Norbeck DW. Inhibition of 3C protease from human rhinovirus strain 1B by peptidyl bromomethylketonehydrazides. Arch Biochem Biophys 1999;362:363-375.
337. Venkatraman S, Kong J, Nimkar S, Wang QM, Aube J, Hanzlik RP. Design, synthesis, and evaluation of azapeptides as substrates and inhibitors for human rhinovirus 3C protease. Bioorg Med Chem Lett 1999;9:577-580.
338. Hill RD, ederas JC. Azodicarboxamides: A new class of cysteine proteinase inhibitor for hepatitis A virus and human rhinovirus 3C enzymes. J Org Chem 1999;64:9538-9546.
339. Murray MA, Janc JW, Venkatraman S, Babe LM. Peptidyl diazomethyl ketones inhibit the human rhinovirus 3C protease: Effect on virus yield by partial block of P3 polyprotein processing. Antivir Chem Chemother 2001;12:273-281.
340. Esser RE, Angelo RA, Murphey MD, Watts LM, Thornburg LP, Palmer JT, Talhouk JW, Smith RE. Cysteine proteinase inhibitors decrease articular cartilage and bone destruction in chronic inflammatory arthritis. Arthritis Rheum 1994;37:236-247.
341. McGrath ME, Eakin AE, Engel JC, McKerrow JH, Craik CS, Fletterick RJ. The crystal structure of cruzain: A therapeutic target for Chagas' disease. J Mol Biol 1995;247:251-259.
342. Richer JK, Hunt WG, Sakanari JA, Grieve RB. Dirofilaria immitis: Effect of fluoromethyl ketone cysteine protease inhibitors on the third- to fourth-stage molt. Exp Parasitol 1993;76:221-231.
343. Morris TS, Frormann S, Shechosky S, Lowe C, Lall MS, Gauss-Muller V, Purcell RH, Emerson SU, Vederas JC, Malcolm BA. In vitro and ex vivo inhibition of hepatitis Avirus 3C proteinase by a peptidyl monofluoromethyl ketone. Bioorg Med Chem 1997;5:797-807.
344. Ramtohul YK, James MN, Vederas JC. Synthesis and evaluation of keto-glutamine analogues as inhibitors of hepatitis Avirus 3C proteinase. J Org Chem 2002;67:3169-3178.
345. Jain RP, Vederas JC. Structural variations in keto-glutamines for improved inhibition against hepatitis A virus 3C proteinase. Bioorg Med Chem Lett 2004;14:3655-3658.
346. Caselli A, Camici G, Manao G, Moneti G, Pazzagli L, Cappugi G, Ramponi G. Nitric oxide causes inactivation of the low molecular weight phosphotyrosine protein phosphatase. J Biol Chem 1994;269:24878-24882.
347. Xian M, Wang QM, Chen X, Wang K, Wang PG. S-nitrosothiols as novel, reversible inhibitors of human rhinovirus 3C protease. Bioorg Med Chem Lett 2000;10:2097-2100.
348. Mckendrick JE, Frormann S, Luo C, Semchuck P, Vederas JC, Malcolm BA. Rapid mass spectrometric determination of preferred irreversible proteinase inhibitors in combinatorial libraries. Int J Mass Spectrom 1998;176:113-124.
349. Bergmann EM, Cherney MM, Mckendrick J, Frormann S, Luo C, Malcolm BA, Vederas JC, James MN. Crystal structure of an inhibitor complex of the 3C proteinase from hepatitis A virus (HAV) and implications for the polyprotein processing in HAV. Virology 1999;265:153-163.
350. Chen SH, Lamar J, Victor F, Snyder N, Johnson R, Heinz BA, Wakulchik M, Wang QM. Synthesis and evaluation of tripeptidyl alpha-ketoamides as human rhinovirus 3C protease inhibitors. Bioorg Med Chem Lett 2003;13:3531-3536.
351. Dragovich PS, Prins TJ, Zhou R, Brown EL, Maldonado FC, Fuhrman SA, Zalman LS, Tuntland T, Lee CA, Patick AK, Matthews DA, Hendrickson TF, Kosa MB, Liu B, Batugo MR, Gleeson JP, Sakata SK, Chen L, Guzman MC, Meador JW III, Ferre RA, Worland ST. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 6. Structure-activity studies of orally bioavailable, 2-pyridone-containing peptidomimetics. J Med Chem 2002;45:1607-1623.
352. Dragovich PS, Prins TJ, Zhou R, Johnson TO, Hua Y, Luu HT, Sakata SK, Brown EL, Maldonado FC, Tuntland T, Lee CA, Fuhrman SA, Zalman LS, Patick AK, Matthews DA, Wu EY, Guo M, Borer BC, Nayyar NK, Moran T, Chen L, Rejto PA, Rose PW, Guzman MC, Dovalsantos EZ, Lee S, McGee K, Mohajeri M, Liese A, Tao J, Kosa MB, Liu B, Batugo MR, Gleeson JP, Wu ZP, Liu J, Meador JW III, Ferre RA. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 8. Pharmacological optimization of orally bioavailable 2-pyridone-containing peptidomimetics. J Med Chem 2003;46:4572-4585.
353. Dragovich PS, Prins TJ, Zhou R, Johnson TO, Brown EL, Maldonado FC, Fuhrman SA, Zalman LS, Patick AK, Matthews DA, Hou X, Meador JW, Ferre RA, Worland ST. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. Part 7: Structure-activity studies of bicyclic 2-pyridone-containing peptidomimetics. Bioorg Med Chem Lett 2002;12:733-738.
354. Patick AK. Rhinovirus chemotherapy. Antiviral Res 2006;71:391-396.
355. Reich SH, Johnson T, Wallace MB, Kephart SE, Fuhrman SA, Worland ST, Matthews DA, Hendrickson TF, Chan F, Meador J III, Ferre RA, Brown EL, DeLisle DM, Patick AK, Binford SL, Ford CE. Substituted benzamide inhibitors of human rhinovirus 3C protease: Structure-based design, synthesis, and biological evaluation. J Med Chem 2000;43:1670-1683.
356. Webber SE, Tikhe J, Worland ST, Fuhrman SA, Hendrickson TF, Matthews DA, Love RA, Patick AK, Meador JW, Ferre RA, Brown EL, DeLisle DM, Ford CE, Binford SL. Design, synthesis, and evaluation of nonpeptidic inhibitors of human rhinovirus 3C protease. J Med Chem 1996;39:5072-5082.
357. Skiles JW, McNeil D. Spiro indolinone beta-lactams, inhibitors of poliovirus and rhinovirus 3C-proteinases. Tetrahedron Lett 1990;31:7277-7280.
358. Jungheim LN, Cohen JD, Johnson RB, Villarreal EC, Wakulchick M, Loncharich RJ, Wang QM. Inhibition of human rhinovirus 3C protease by homophtalamides. Bioorg Med Chem Lett 1997;7:1589-1594.
359. Lowe C, Vederas JC. Naturally-occurring beta-lactones-Occurrence, syntheses and properties - A review. Org Prep Proc Int 1995;27:305-346.
360. Lall MS, Karvellas C, Vederas JC. Beta-lactones as a newclass of cysteine proteinase inhibitors: Inhibition of hepatitis A virus 3C proteinase by N-Cbz-serine beta-lactone. Org Lett 1999;1:803-806.
361. Lall MS, Ramtohul YK, James MN, Vederas JC. Serine and threonine beta-lactones: A new class of hepatitis A virus 3C cysteine proteinase inhibitors. J Org Chem 2002;67:1536-1547.
362. Lall MS, Jain RP, Vederas JC. Inhibitors of 3C cysteine proteinases from Picornaviridae. Curr Top Med Chem 2004;4:1239-1253.
363. Ramtohul YK, Martin NI, Silkin L, James MNG, Vederas JC. Synthesis of pseudoxazolones and their inhibition of the 3C cysteine proteinases from hepatitis A virus and human rhinovirus-14. J Chem Soc Perkin Trans 2002;1:1351-1359.
364. Johnson TO, Hua Y, Luu HT, Brown EL, Chan F, Chu SS, Dragovich PS, Eastman BW, Ferre RA, Fuhrman SA, Hendrickson TF, Maldonado FC, Matthews DA, Meador JW III, Patick AK, Reich SH, Skalitzky DJ, Worland ST, Yang M, Zalman LS. Structure-based design of a parallel synthetic array directed toward the discovery of irreversible inhibitors of human rhinovirus 3C protease. J Med Chem 2002;45:2016-2023.
365. Brill GM, Kati WM, Montgomery D, Karwowski JP, Humphrey PE, Jackson M, Clement JJ, Kadam S, Chen RH, McAlpine JB. Novel triterpene sulfates from Fusarium compactum using a rhinovirus 3C protease inhibitor screen. J Antibiot (Tokyo) 1996;49:541-546.
366. Kadam S, Poddig J, Humphrey P, Karwowski J, Jackson M, Tennent S, Fung L, Hochlowski J, Rasmussen R, McAlpine J. Citrinin hydrate and radicinin: Human rhinovirus 3C-protease inhibitors discovered in a target-directed microbial screen. J Antibiot (Tokyo) 1994;47:836-839.
367. Singh SB, Cordingley MG, Ball RG, Smith JL, Dombrowski AW, Goetz MA. Structure and stereochemistry of thysanone - A novel human rhinovirus 3c-protease inhibitor from thysanophorapenicilloides. Tetrahedron Lett 1991;32:5279-5282.
368. Konig H, Rosenwirth B. Purification and partial characterization of poliovirus protease 2A by means of a functional assay. J Virol 1988;62:1243-1250.
369. Molla A, Hellen CU, Wimmer E. Inhibition of proteolytic activity of poliovirus and rhinovirus 2A proteinases by elastase-specific inhibitors. J Virol 1993;67:4688-4695.
370. Wang QM, Johnson RB, Jungheim LN, Cohen JD, Villarreal EC. Dual inhibition of human rhinovirus 2A and 3C proteases by homophthalimides. Antimicrob Agents Chemother 1998;42:916-920.
371. Slee EA, Zhu H, Chow SC, MacFarlane M, Nicholson DW, Cohen GM. Benzyloxycarbonyl-Val-Ala-Asp (OMe) fluoromethylketone (Z-VAD.FMK) inhibits apoptosis by blocking the processing of C PP32. Biochem J 1996;315(Pt 1):21-24.
372. Deszcz L, Seipelt J, Vassilieva E, Roetzer A, Kuechler E. Antiviral activity of caspase inhibitors: Effect on picornaviral 2A proteinase. FEBS Lett 2004;560:51-55.
373. Gerzon K, Ryan C, DeLong D. Method of virus suppression by hydantoins. 3,790,6733. 1974; Ref Type: Patent.
374. Vance LM, Moscufo N, Chow M, Heinz BA. Poliovirus 2C region functions during encapsidation of viral RNA. J Virol 1997;71:8759-8765.
375. Verlinden Y, Cuconati A, Wimmer E, Rombaut B. The antiviral compound 5-(3,4-dichlorophenyl) methylhydantoin inhibits the post-synthetic cleavages and the assembly of poliovirus in a cell-free system. Antiviral Res 2000;48:61-69.
376. Kolatkar PR, Bella J, Olson NH, Bator CM, Baker TS, Rossmann MG. Structural studies of two rhinovirus serotypes complexed with fragments of their cellular receptor. EMBO J 1999;18:6249-6259.